Norske tall for brystkreftdødelighet og validitet i svenske mammografistudier;Norwegian breast cancer mortality rates and validity in Swedish mammography trials

Tidsskrift for den Norske Laegeforening

Volumn 121, Issue 16, 2001, Pages 1928-1931

  Zahl, Per Henrik ^a   Kopjar, Branko ^a   Mæhlen, Jan ^b  

^a NORWEGIAN INSTITUTE OF PUBLIC HEALTH   (Norway)

^b ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

AGED; ARTICLE; BREAST TUMOR; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; EPIDEMIOLOGY; FEMALE; HUMAN; MAMMOGRAPHY; MASS SCREENING; MIDDLE AGED; MORTALITY; NORWAY; RADIOGRAPHY; RANDOMIZED CONTROLLED TRIAL; STATISTICAL MODEL; SURVIVAL RATE; SWEDEN; VALIDATION STUDY;

AGED; BIAS (EPIDEMIOLOGY); BREAST NEOPLASMS; FEMALE; HUMANS; MAMMOGRAPHY; MASS SCREENING; MIDDLE AGED; MODELS, STATISTICAL; NORWAY; RANDOMIZED CONTROLLED TRIALS; SURVIVAL RATE; SWEDEN;

EID: 0035919445     PISSN: 00292001     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Zahl P-H. Brystkreft - insidens, mortalitet og stadiemigrasjon i Norge. Tidsskr Nor Lægeforen 1997; 117: 3765-7.
2. Nyström L, Rutqvist LE, Wall S, Lindgren A, Lindqvist M, Ryden S et al. Breast cancer screening with mammography: an overview of the Swedish randomised trials. Lancet 1993; 341: 973-8.
3. Chu KC, Smart CR, Tarone RE. Analysis of breast cancer mortality and stage distribution by age for the Health Insurance Plan clinical trial. J Natl Cancer Inst 1988; 80: 1125-32.
4. Alexander FE, Anderson TJ, Broen HK, Forrest AP, Hepburn W, Kirkpatrick AE et al. 14 years of follow-up from the Edinburgh randomized trial of breast cancer screening. Lancet 1999; 353: 1903-8.
5. Miller AB, To T, Baines CJ, Wall C. Canadian national breast screening srudy-2:13-year results of a randomized trial in women ages 50-59 years. J Natl Cancer Inst 2000; 92: 1490-9.
6. Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias: dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 1995; 273: 408-12.
7. Moher D, Pham B, Jones A, Cook DJ, Jadad A, Moher M. Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analysis? Lancet 1998; 352: 609-13.
8. Sjönell G, Ståhle L. Hälsokontroller med mammografi minskar inte dödelighet i bröstcancer. Läkartidningen 1999; 96: 904-13.
9. Hakama M, Pukkala E, Söderman B, Day N. Implementation of a screening as a public health policy: issues in design and evaluation. J Med Screening 1999; 6: 209-16.
10. Broeders MJM, Peer PGM, Stratman H, Beex LVAM, Hendriks JHCL, Holland R et al. Diverging breast cancer mortality rates in relation to screening? A comparison of Nijmegen to Arnheim and the Netherlands, 1996-97. Int J Cancer 2001; 92: 303-8.
11. Blanks RG, Moss SM, McGahan CE, Quinn MJ, Babb PJ. Effect of NHS breast screening programme on mortality from breast cancer in England and Wales, 1990-8: comparison of observed with predicted mortality. BMJ 2000; 321: 665-69.
12. Gøtzsche PC, Olsen O. Is screening for breast cancer with mammography justifiable? Lancet 2000; 355: 129-34.
13. Tabár L, Fagerberg CJG, Gad A, Baldetorp L, Holmberg LH, Gröntoft O et al. Reduction in mortality from breast cancer after mass screening with mammography. Lancet 1985; 1: 829-32.
14. Wang H, Hofvind SSH, Thoresen SØ. Prøveprosjekt med mammografi - resultater fra første undersøkelse. Tidsskr Nor Lægeforen 2000; 120: 3237-40.
15. Aalen OO. Innføring i statistikk. Oslo: Ad Notam, Gyldendal, 1994.
16. Cancer in Norway 1993. Oslo: Kreftregisteret 1996.
17. Zahl P-H, Tretli S. Long-term survival of breast cancer in Norway by age and clinical stage. Stat Med 1997; 16: 1435-49.
18. Hermon C, Beral V. Breast cancer mortality rates are levelling off or beginning to decline in many western countries: analysis of time-trends, age-cohort and age-period models of breast cancer mortality in 20 countries. Br J Cancer 1996; 73: 955-60.
19. Engeland A, Haldorsen T, Tretli S, Hakulinen T, Hørte LG, Luostarinen T et al. Prediction of cancer mortality in the Nordic countries up to the years 2000 and 2010. APMIS supplementum 1995; 103, nr 49.
20. Ederer F, Axtell LM, Cutler S. The relative survival rate: a statistical methodology. Natl Cancer Inst Monographs 1961; 101-21.
21. Tabár L, Fagerberg G, Chen H, Duffy SW, Smart CR, Gad A et al. Efficacy of breast cancer screening by age. Cancer 1995; 75: 2507-17.
22. Tabár L, Fagerberg G, Duffy SW, Day NE, Gad A, Grötoft O. Update of the Swedish two-county program of mammographic screening for breast cancer. Radiol Clin North Am 1992; 30: 187-210.
23. Mittra I, Baum M, Thornton H, Houghton J. Is clinical breast examination an acceptable alternative to mammographic screening? BMJ 2000; 321: 1071-3.
24. Karjalainen S, Pukkala E. Social class as a prognostic factor in breast cancer survival. Cancer 1990; 66: 819-26.
25. Enkvist C. Vad er rimelig screening? Läkartidningen 1995; 92: 4540-1.
26. Einhorn J. Gör en oberoende utvärding av mammografiverksamheten! Läkartidningen 2000; 97: 1366-7.